Research answers to the National Cancer Institute’s provocative questions (R21 clinical trial optional); There is an R01 opportunity (clinical trial optional) as well.

The National Cancer Institute invites applications for its research answers to provocative questions (R21 clinical trial optional) funding opportunity. This supports research projects designed to solve specific problems and paradoxes in cancer research. These are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Each application must address one of the following questions:

  • what the underlying causes of the unexplained rising incidence in early-onset cancer are;
  • how intermittent fasting affects cancer incidence, treatment response or outcome;
  • how selective pressures affect cell competition and cooperation during cancer initiation and development;
  • what mechanisms explain sex difference in cancer incidence, lesion location or response to therapy;
  • what strategies can block or reverse the emergence of new cell lineage states induced by cancer treatments;
  • how cancer cachexia can be reversed;
  • what methods can be developed to integrate patient-generated health data into electronic health records;
  • what strategies improve and sustain coordination of comprehensive healthcare for underserved cancer patients with comorbidities;
  • what methods can be developed to effectively study small or rare populations relevant to cancer research.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

The total budget for 2021 is USD 3 million, covering eight to 12 grants. Direct costs are limited to USD 275,000 per project over a two-year period, with no more than USD 200,000 in direct costs allowed in any single year. The total project period may not exceed two years.

Click here to visit funders website.

Closing date: 30 April 2020

Leave a Reply